Bone Biologics Corp (BBLG): Price and Financial Metrics
BBLG Price/Volume Stats
| Current price | $0.57 | 52-week high | $32.40 |
| Prev. close | $0.62 | 52-week low | $0.55 |
| Day low | $0.55 | Volume | 153,800 |
| Day high | $0.60 | Avg. volume | 156,558 |
| 50-day MA | $0.90 | Dividend yield | N/A |
| 200-day MA | $5.07 | Market Cap | 1.79M |
BBLG Stock Price Chart Interactive Chart >
Bone Biologics Corp (BBLG) Company Bio
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Latest BBLG News From Around the Web
Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.
Bone Biologics Provides Scientific Update on NB1 Bone Graft DeviceBURLINGTON, Mass., September 26, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device. |
Insider Buying: CFO Deina Walsh Acquires 8,000 Shares of Bone Biologics Corp (BBLG)On September 13, 2023, Deina Walsh, the Chief Financial Officer (CFO) of Bone Biologics Corp (NASDAQ:BBLG), made a significant insider purchase of 8,000 shares of the company. |
CEO Jeff Frelick Buys 9,500 Shares of Bone Biologics Corp (BBLG)On September 11, 2023, Jeff Frelick, the CEO of Bone Biologics Corp (NASDAQ:BBLG), purchased 9,500 shares of the company, marking a significant insider buying activity. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday! |
BBLG Advances Crucial Technology and Solidifies FundingBy Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) recently announced that it has received approval to begin pilot clinical trials with NB1 in spinal fusion patients. The approval was given by the Human Research Ethics Committee and the trials will take place in Australia. This is an important and exciting step for Bone as the study will evaluate the |
BBLG Price Returns
| 1-mo | -15.00% |
| 3-mo | -60.69% |
| 6-mo | -92.69% |
| 1-year | -98.26% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -90.94% |
| 2022 | -94.04% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...